Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 170,100 shares, a decrease of 18.3% from the November 30th total of 208,100 shares. Based on an average daily trading volume, of 306,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.2% of the shares of the company are sold short.

Tiziana Life Sciences Trading Down 4.2 %

Shares of NASDAQ:TLSA traded down $0.03 during mid-day trading on Friday, reaching $0.67. 788,226 shares of the company traded hands, compared to its average volume of 227,787. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74. The company’s 50 day moving average price is $0.93 and its 200-day moving average price is $0.95.

Institutional Trading of Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC boosted its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 69,387 shares of the company’s stock after buying an additional 13,500 shares during the period. Zhang Financial LLC owned 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent SEC filing.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.